Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions: ER-100 epigenetic therapy; Genetic
Lead sponsor: Life Biosciences Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Glendale, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Uveal Melanoma, Radiation Retinopathy, Radiation Maculopathy
Interventions: Ranibizumab; Drug
Lead sponsor: Shields, Shields and Associates; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: ARB, BVMD, Autosomal-Dominant Bestrophinopathy, Best Vitelliform Macular Dystrophy
Interventions: OPGx-BEST1; Genetic
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Los Angeles, California • Gainsville, Florida • New York, New York + 2 more

Conditions: Retinoblastoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, mesna, vincristine sulfate; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Sevirumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 6
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 3 more

Conditions: Macular Degeneration
Interventions: Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis
Interventions: AAV2-hRPE65v2,voretigene neparvovec-rzyl; Biological
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 2
States / cities: Iowa City, Iowa • Philadelphia, Pennsylvania

Conditions: Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
Interventions: Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%; Drug · Procedure
Lead sponsor: Harrow Inc; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Tyler, Texas

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • San Diego, California + 12 more

Conditions: Geographic Atrophy of the Macula
Interventions: GAL-101, Placebo; Drug
Lead sponsor: Galimedix Therapeutics Inc; Industry
Eligibility: 55 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions: amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC); Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year to 45 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cataract
Interventions: Tecnis Symfony OptiBlue/ Tecnis Symfony OptiBlue toric IOL; Device
Lead sponsor: Coastal Eye Surgeons PLLC; Other
Eligibility: 50 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Greenwich, Connecticut

Conditions: Optical Coherence Tomography of Retina, Alzheimer Disease
Interventions: retinal imaging with low-cost OCT-a/LCI device; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Retinitis Pigmentosa
Interventions: Lutein, Cornstarch control; Drug · Dietary Supplement
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Retinal Degeneration, Age-Related Macular Degeneration, Retinitis Pigmentosa, Hydroxychloroquine Retinopathy, Usher Syndromes, Late-Onset Retinal Degeneration, Cone Dystrophy, Cone Rod Dystrophy, Rod Cone Dystrophy, Rod Dystrophy
Interventions: Adaptive optics imaging; Device
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 21 Years and older
Enrollment: 100 participants
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Bethesda, Maryland • Silver Spring, Maryland

Conditions: Age-Related Macular Degeneration
Interventions: Loteprednol Etabonate Ophthalmic Gel [Lotemax], Refresh Lubricant Eye Drops [Artificial Tears]; Drug · Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug; Procedure · Drug
Lead sponsor: Retina Vitreous Associates of Florida; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Dry Age-Related Macular Degeneration, Geographic Atrophy
Interventions: iPSC-derived RPE/PLGA transplantation; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 55 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Baltimore, Maryland • Bethesda, Maryland

Conditions: Glaucoma, Diabetic Retinopathy, Refractive Errors, Cataract, Behavior, Health
Interventions: No Financial Incentive, Financial Incentive; Other · Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neovascular Age-related Macular Degeneration
Interventions: 2.0 mg OPT-302, 2.0 aflibercept, Sham; Biological · Procedure
Lead sponsor: Opthea Limited; Industry
Eligibility: 50 Years and older
Enrollment: 998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 60
States / cities: Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more

Conditions: Vitrectomy, Macular Pucker, Retinal Edema
Interventions: Dexamethasone Intracanalicular Insert, 0.4 mg, Prednisone acetate 1%; Drug
Lead sponsor: Kovach Eye Institute; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Elmhurst, Illinois

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Acyclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 2
States / cities: Chicago, Illinois

Search by objective public record fields.

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

Chemotherapy in Treating Patients With Retinoblastoma

A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training

A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access

A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Visual Outcomes of Tecnis Symfony Opti-Blue EDOF Intraocular Lens (IOL)

Comparative Study of High Performance Low-Cost Optical Coherence Tomography (Stage 1B, 2 and 3)

Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A

Adaptive Optics Imaging of Outer Retinal Diseases

The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.

Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS